JPWO2021156180A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021156180A5 JPWO2021156180A5 JP2022542952A JP2022542952A JPWO2021156180A5 JP WO2021156180 A5 JPWO2021156180 A5 JP WO2021156180A5 JP 2022542952 A JP2022542952 A JP 2022542952A JP 2022542952 A JP2022542952 A JP 2022542952A JP WO2021156180 A5 JPWO2021156180 A5 JP WO2021156180A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- cancer
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20155161.1 | 2020-02-03 | ||
| EP20155161 | 2020-02-03 | ||
| PCT/EP2021/052263 WO2021156180A1 (en) | 2020-02-03 | 2021-02-01 | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512175A JP2023512175A (ja) | 2023-03-24 |
| JPWO2021156180A5 true JPWO2021156180A5 (es) | 2024-02-08 |
Family
ID=69467427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542952A Pending JP2023512175A (ja) | 2020-02-03 | 2021-02-01 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230131720A1 (es) |
| EP (1) | EP4100412A1 (es) |
| JP (1) | JP2023512175A (es) |
| CN (1) | CN115052881B (es) |
| WO (1) | WO2021156180A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11608343B2 (en) * | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| CN114621221B (zh) * | 2022-03-12 | 2022-10-11 | 陕西海辰风扬医药科技有限公司 | 妥卡替尼关键中间体及其制备方法 |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1465632A1 (en) * | 2001-12-12 | 2004-10-13 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
| CA2544863A1 (en) * | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| US8648087B2 (en) * | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| US10227342B2 (en) | 2014-06-19 | 2019-03-12 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| JP6863901B2 (ja) | 2015-05-13 | 2021-04-28 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| US11186574B2 (en) * | 2017-08-31 | 2021-11-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and/or HER2 and methods of use |
| JP7333313B2 (ja) * | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
-
2021
- 2021-02-01 CN CN202180012676.0A patent/CN115052881B/zh active Active
- 2021-02-01 EP EP21703191.3A patent/EP4100412A1/en active Pending
- 2021-02-01 US US17/759,890 patent/US20230131720A1/en active Pending
- 2021-02-01 WO PCT/EP2021/052263 patent/WO2021156180A1/en unknown
- 2021-02-01 JP JP2022542952A patent/JP2023512175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101001629B (zh) | 药物组合物 | |
| ES2747941T3 (es) | Formulaciones galénicas de compuestos orgánicos | |
| TWI324928B (en) | Pharmaceutical composition for the treatment of cancer | |
| JP4875277B2 (ja) | 放出ｐＨ域及び／又は速度制御組成物 | |
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| CN101616905B (zh) | 苯并呋喃杀寄生物剂 | |
| JP4588973B2 (ja) | 経口投与用製剤 | |
| JPWO2021156180A5 (es) | ||
| JPWO2021156178A5 (es) | ||
| US20060160783A1 (en) | Novel omeprazole forms and related methods | |
| CN110613726B (zh) | 核苷化合物的应用 | |
| EP2359816B1 (en) | Aripiprazole formulations | |
| JP5721093B2 (ja) | 崩壊錠 | |
| JP2814513B2 (ja) | 溶出性の改良された製剤組成物 | |
| AU2008303504B2 (en) | Galenical formulations of Aliskiren | |
| CN101600687B (zh) | 抗寄生物剂 | |
| KR20130078147A (ko) | 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물 | |
| CN103864762B (zh) | 3,6-双（吡啶-4-基乙炔基）咔唑衍生物及其制备方法和应用 | |
| JP2019503373A (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP2000344665A (ja) | 鎮痛剤 | |
| WO2023238929A1 (ja) | ピミテスピブを含有する医薬組成物 | |
| JP2018020968A (ja) | ゲフィチニブを有効成分とする医薬組成物 | |
| JP2019503366A (ja) | キノリン誘導体またはその塩を含有する医薬組成物 | |
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| JP2002518330A (ja) | 処置方法 |